Zacks Reaffirms Neutral Rating on Haemonetics (HAE)

By admin | 6 years ago

Haemonetics (NYSE: HAE)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Wednesday. They currently have a $74.00 price target on the stock.

Several other analysts have also recently commented on the stock. Analysts at Stephens upgraded shares of Haemonetics from an “equal weight” rating to an “overweight” rating in a research note to investors on Tuesday, May 1st. Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Haemonetics from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday, May 1st. They now have a $55.00 price target on the stock. Finally, analysts at Raymond James (NYSE: RJF) initiated coverage on shares of Haemonetics in a research note to investors on Wednesday, April 25th. They set a “market perform” rating on the stock.

Haemonetics traded down 0.10% on Wednesday, hitting $69.54. Haemonetics has a 52-week low of $54.99 and a 52-week high of $71.50. The company has a market cap of $1.762 billion and a price-to-earnings ratio of 26.88.

Haemonetics last announced its earnings results on Monday, April 30th. The company reported $0.80 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.83 by $0.03. Haemonetics’s revenue was up 9.8% compared to the same quarter last year. On average, analysts predict that Haemonetics will post $0.80 earnings per share next quarter.

Haemonetics Corporation is a medical device company. It is engaged in developing and manufacturing automated blood component collection devices and surgical blood salvage devices.

About the author